Analysts at Jefferies Group cut their price objective on shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) from $20.00 to $19.00 in a research report issued to clients and investors on Tuesday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 340.84% from the stock’s previous close.
A number of other analysts have also recently weighed in on SNTA. Analysts at BMO Capital Markets cut their price target on shares of Synta Pharmaceuticals Corp. from $9.00 to $5.00 in a research note to investors on Tuesday. Separately, analysts at MLV Capital cut their price target on shares of Synta Pharmaceuticals Corp. from $16.00 to $10.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at JMP Securities raised their price target on shares of Synta Pharmaceuticals Corp. from $11.00 to $14.00 in a research note to investors on Monday, October 28th. They now have a “market outperform” rating on the stock. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $13.33.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) traded up 4.87% on Tuesday, hitting $4.31. The stock had a trading volume of 1,875,288 shares. Synta Pharmaceuticals Corp. has a 1-year low of $3.76 and a 1-year high of $11.88. The stock’s 50-day moving average is $6.23 and its 200-day moving average is $6.34. The company’s market cap is $297.6 million.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) last released its earnings data on Monday, November 4th. The company reported ($0.33) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.31) by $0.02. On average, analysts predict that Synta Pharmaceuticals Corp. will post $-1.22 earnings per share for the current fiscal year.
Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.